Shinpoong, MMV launch Phase III clinical trials for anti-malaria drug

Published: 2007-05-09 06:56:00

Updated: 2007-05-09 06:56:00

Shinpoong Pharm and the Medicines for Malaria Venture (MMV) are conducting the Phase III clinical trials for PYRAMAX, pyronaridine-artesunate, a new artemisinin-based combination treatment (ACT) for malaria.

The studies will involve over 3,000 children, adolescents, and adults in more than 12 ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK